Accounts Receivable, after Allowance for Credit Loss, Current of Novo Integrated Sciences, Inc. from 31 Aug 2016 to 31 Aug 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Novo Integrated Sciences, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Aug 2016 to 31 Aug 2024.
  • Novo Integrated Sciences, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Aug 2024 was $1,916,819, a 31% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Novo Integrated Sciences, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $1,916,819 +$449,791 +31% 31 Aug 2024 10-K 18 Dec 2024 2024 FY
Q2 2024 $2,251,528 +$923,915 +70% 31 May 2024 10-Q 19 Jul 2024 2024 Q3
Q1 2024 $2,153,914 +$1,230,358 +133% 29 Feb 2024 10-Q 15 Apr 2024 2024 Q2
Q4 2023 $2,636,174 +$1,676,083 +175% 30 Nov 2023 10-Q 22 Jan 2024 2024 Q1
Q3 2023 $1,467,028 +$449,623 +44% 31 Aug 2023 10-K 18 Dec 2024 2024 FY
Q2 2023 $1,327,613 -$3,838,626 -74% 31 May 2023 10-Q 17 Jul 2023 2023 Q3
Q1 2023 $923,556 -$328,417 -26% 28 Feb 2023 10-Q 26 May 2023 2023 Q2
Q4 2022 $960,091 -$736,120 -43% 30 Nov 2022 10-Q 24 May 2023 2023 Q1
Q3 2022 $1,017,405 -$451,024 -31% 31 Aug 2022 10-K 14 Dec 2023 2023 FY
Q2 2022 $5,166,239 +$3,870,513 +299% 31 May 2022 10-Q 14 Jul 2022 2022 Q3
Q1 2022 $1,251,973 -$160,768 -11% 28 Feb 2022 10-Q 13 Apr 2022 2022 Q2
Q4 2021 $1,696,211 +$235,372 +16% 30 Nov 2021 10-Q 18 Jan 2022 2022 Q1
Q3 2021 $1,468,429 -$264,003 -15% 31 Aug 2021 10-K 03 Apr 2023 2022 FY
Q2 2021 $1,295,726 +$178,654 +16% 31 May 2021 10-Q 14 Jul 2021 2021 Q3
Q1 2021 $1,412,741 -$59,608 -4% 28 Feb 2021 10-Q 14 Apr 2021 2021 Q2
Q4 2020 $1,460,839 -$172,098 -11% 30 Nov 2020 10-Q 13 Jan 2021 2021 Q1
Q3 2020 $1,732,432 +$268,903 +18% 31 Aug 2020 10-K 14 Dec 2021 2021 FY
Q2 2020 $1,117,072 -$265,957 -19% 31 May 2020 10-Q 14 Jul 2020 2020 Q3
Q1 2020 $1,472,349 +$93,455 +6.8% 29 Feb 2020 10-Q 20 Apr 2020 2020 Q2
Q4 2019 $1,632,937 +$227,648 +16% 30 Nov 2019 10-Q 13 Jan 2020 2020 Q1
Q3 2019 $1,463,529 +$125,984 +9.4% 31 Aug 2019 10-K 09 Dec 2020 2020 FY
Q2 2019 $1,383,029 +$71,455 +5.4% 31 May 2019 10-Q 11 Jul 2019 2019 Q3
Q1 2019 $1,378,894 +$30,047 +2.2% 28 Feb 2019 10-Q 11 Apr 2019 2019 Q2
Q4 2018 $1,405,289 +$116,330 +9% 30 Nov 2018 10-Q 11 Jan 2019 2019 Q1
Q3 2018 $1,337,545 +$208,647 +18% 31 Aug 2018 10-K 20 Nov 2019 2019 FY
Q2 2018 $1,311,574 +$456,655 +53% 31 May 2018 10-Q 11 Jul 2018 2018 Q3
Q1 2018 $1,348,847 28 Feb 2018 10-Q 12 Apr 2018 2018 Q2
Q4 2017 $1,288,959 30 Nov 2017 10-Q 12 Jan 2018 2018 Q1
Q3 2017 $1,128,898 +$343,118 +44% 31 Aug 2017 10-K 06 Nov 2018 2018 FY
Q2 2017 $854,919 31 May 2017 10-Q 24 Jul 2017 2017 Q3
Q3 2016 $785,780 31 Aug 2016 10-K 08 Dec 2017 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.